Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 10/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753918 | 0.85 | TAF1 (0.48) | JAK1JAK2IDO1P2RX7 | |
| SCHEMBL19639663 | 0.83 | KDM4E (0.46) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL19639671 | 0.72 | BRD4 (0.51) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17749037 | 0.72 | LIMK2 (0.49) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL17729981 | 0.72 | SMN1; SMN2 (0.60) | — | |
| SCHEMBL17749043 | 0.71 | CECR2 (0.53) | P2RX7 | |
| SCHEMBL17749003 | 0.69 | BRD9 (0.61) | P2RX7 | |
| SCHEMBL17749004 | 0.69 | TAF1 (0.55) | JAK1JAK2TYK2 | |
| SCHEMBL17753688 | 0.68 | KDM4E (0.55) | JAK1JAK2TYK2 | |
| SCHEMBL13549258 | 0.67 | USP2 (0.41) | JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | JAK1 169/4885JAK2 55/4885IDO1 3600/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | JAK1 169/4885JAK2 55/4885IDO1 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.